Integra Lifesciences Holdings (IART) Fundamental Analysis: Revenue, Earnings & Valuation

7.87 / 10

Outperform

Fundamental analysis rates IART as Outperform with a 7.9/10 score. Profit‑MV and Asset‑MV are strong (scores 2), supporting profitability and asset base. Cash‑MV and Cash‑UP are negative, indicating liquidity pressure. ROE metrics are low, but overall fundamentals remain satisfactory.

Analysis Checks(8/10)

ROA (%)

Value-13.52

Score2/3

Weight13.84%

1M Return0.63%

Annualized return on equity (%)

Value-39.90

Score2/3

Weight30.73%

1M Return1.35%

Profit-MV

Value0.68

Score2/3

Weight76.93%

1M Return3.26%

Cash-UP

Value-1.52

Score2/3

Weight-70.16%

1M Return-3.92%

Annualized net profit margin on total assets (%)

Value-13.52

Score2/3

Weight13.84%

1M Return0.63%

ROE (diluted) (%)

Value-49.50

Score2/3

Weight24.92%

1M Return1.11%

Asset-MV

Value-0.55

Score2/3

Weight82.22%

1M Return3.42%

ROE (%)

Value-39.90

Score2/3

Weight30.73%

1M Return1.35%

Cash-MV

Value-1.00

Score1/3

Weight-60.49%

1M Return-3.56%

Net profit / Total profit (%)

Value91.65

Score1/3

Weight-42.58%

1M Return-2.37%

Is IART fundamentally strong?

IART scores 7.87/10 on fundamentals and holds a Discounted valuation at present. Backed by its -39.90% ROE, -31.58% net margin, -1.44 P/E ratio, 0.71 P/B ratio, and -7388.89% earnings growth, these metrics solidify its Outperform investment rating.